Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Mar 20, 2018 11:51am

139 Views

Post# 27746776

RE:Dr Wallace

Do we have any partnership agreements covering South Korea?
Could you imagine another deal, what would it look like now? how much would htat boost up the value for the larger USA deal yet to come?
Looking back at previoius releases, the plan was for a deal within 6 months of Oct 2017.

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

OCTOBER 20, 2017

Although it is Antibe’s goal to execute one or more regional licensing deals in the next six months, there can be no assurance that any partnering discussions will materialize into a successful transaction.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading